Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Kelly Stratton MD

Kelly L. Stratton MD

Associate Professor of Urologic Oncology, Department of Urology at the Stephenson Cancer Center (SCC), University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

Dr. Stratton is an Associate Professor of Urologic Oncology in the Department of Urology at the Stephenson Cancer Center (SCC) on the University of Oklahoma Health Sciences Center campus. He chairs the SCC’s Data and Safety Monitoring Committee (DSMC) and, in this role, he is responsible for overseeing research participant safety, study conduct, and the validity and integrity of data for institutional and other qualifying clinical trials at SCC. Dr. Stratton works closely with the SCC’s Associate Director for Clinical Research and the Chair of the Protocol Review and Monitoring Committee (PRMC) to ensure that the policies and processes for protocol and data review and monitoring are rigorous, compliant with institutional and federal guidelines, and support the conduct of clinical research at the SCC. As a surgeon, Dr. Stratton provides expertise in the operative management of urologic malignancies. He is also the Medical Director of the Ambulatory Surgery Center where minimally invasive outpatient treatments are performed for urologic cancer patients.

Dr. Stratton's clinical research interests include advanced imaging of localized prostate cancer and new techniques for diagnosing prostate cancer. This has led to a collaboration with Dr. Hanas in the Department of Biochemistry and Molecular Biology and Dr. Xiang in the College of Engineering. To date, they have conducted over 1000 MRI-guided biopsies on patients with suspected prostate cancer. They have developed a recognized program in the focal treatment of prostate cancer that has been located on MRI. The combination of improved detection and focalize treatment has resulted in better outcomes for patients treated with prostate cancer. His collaboration with Dr. Hanas complements these clinical endeavors and could result in new discoveries that have immediate clinical benefits. In addition to evaluating novel approaches to the identification of prostate cancer, Dr. Stratton also manages patients with advanced and metastatic prostate cancer. The implementation of guidelines-based prostate cancer treatment has resulted in increasing patient accrual and enrollment in prostate cancer clinical trials. He is the mentor of urology residents and medical students who share an interest in urologic oncology research. Dr. Stratton is the principal investigator on the protocol, “Improving the Diagnosis and Treatment of Prostate Cancer”.


Dr. Stratton has provided a complete listing of all disclosures, please see attached list.